Abstract
BACKGROUND AND PURPOSE: Conventional MR imaging explains only a fraction of the clinical outcome variance in multiple sclerosis. We aimed to evaluate machine learning models for disability prediction on the basis of radiomic, volumetric, and connectivity features derived from routine brain MR images.
MATERIALS AND METHODS: In this retrospective cross-sectional study, 3T brain MR imaging studies of patients with multiple sclerosis, including 3D T1-weighted and T2-weighted FLAIR sequences, were selected from 2 institutions. T1-weighted images were processed to obtain volume, connectivity score (inferred from the T2 lesion location), and texture features for an atlas-based set of GM regions. The site 1 cohort was randomly split into training (n = 400) and test (n = 100) sets, while the site 2 cohort (n = 104) constituted the external test set. After feature selection of clinicodemographic and MR imaging–derived variables, different machine learning algorithms predicting disability as measured with the Expanded Disability Status Scale were trained and cross-validated on the training cohort and evaluated on the test sets. The effect of different algorithms on model performance was tested using the 1-way repeated-measures ANOVA.
RESULTS: The selection procedure identified the 9 most informative variables, including age and secondary-progressive course and a subset of radiomic features extracted from the prefrontal cortex, subcortical GM, and cerebellum. The machine learning models predicted disability with high accuracy (r approaching 0.80) and excellent intra- and intersite generalizability (r ≥ 0.73). The machine learning algorithm had no relevant effect on the performance.
CONCLUSIONS: The multidimensional analysis of brain MR images, including radiomic features and clinicodemographic data, is highly informative of the clinical status of patients with multiple sclerosis, representing a promising approach to bridge the gap between conventional imaging and disability.
ABBREVIATIONS:
- DD
- disease duration
- EDSS
- Expanded Disability Status Scale
- IQR
- interquartile range
- MAE
- mean absolute error
- ML
- machine learning
- MS
- multiple sclerosis
- WBV
- whole-brain volume
Footnotes
Disclosures: Maria Petracca—UNRELATED: Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: travel sponsorship from Novartis. Nikolaos Petsas—UNRELATED: Consultancy: Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Mediterraneo, Pozzilli, Italy; Employment: Sapienza University of Rome, Italy; Grants/Grants Pending: Onlus Sant’Andrea, Rome, Italy.* Carlo Pozzilli—UNRELATED: Board Membership: Merck, Biogen, Novartis, Bristol Myers Squibb, Almirall, Sanofi, Roche; Consultancy: Novartis; Grants/Grants Pending: Merck, Roche, Biogen*; Payment for Lectures Including Service on Speakers Bureaus: Almirall, Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva; Payment for Manuscript Preparation: Merck, Biogen, Roche; Payment for Development of Educational Presentations: Multiple Sclerosis Paradigm. Vincenzo Brescia Morra—UNRELATED: Consultancy: Biogen, Teva Pharmaceutical Industries, Genzyme, Merck, Novartis and Almirall; Payment for Lectures Including Service on Speakers Bureaus: Biogen, Teva Pharmaceutical Industries, Genzyme, Merck, Novartis, and Almirall. Patrizia Pantano—UNRELATED: Grants/Grants Pending: Fondazione Italiana Sclerosi Multipla, Sapienza University.* Sirio Cocozza—UNRELATED: Board Membership: Amicus Therapeutics, Comments: fees for Advisory Board; Payment for Lectures Including Service on Speakers Bureaus: Sanofi, Amicus, Comments: fees for speaking. *Money paid to the institution.
- © 2021 by American Journal of Neuroradiology